Gilead Sciences, Inc.

“Gilead is a durable, high-FCF HIV franchise trading at a modest ~18% discount to intrinsic value with an unpriced lenacapavir PrEP option, but the combination of a visible Biktarvy patent cliff (2033), persistently poor M&A capital allocation, negligible insider ownership, and expected 5-8% CAGR returns that merely approximate the market make this a track rather than a high-conviction buy — the business is too good to avoid entirely, but not cheap enough or led by the right management team to load the truck.”